Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of phase II trial AIRC-IG-13218.

CONCLUSIONS: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results. Advances in knowledge: The use of mpMRI to identify and boost the DIL is an innovative and interesting approach to PCa. Our preliminary findings suggest that dose escalation using DIL boost and extremely hypofractionated radiotherapy regimens might be a safe approach, allowing for short and effective treatment of organ-confined PCa.
PMID: 29750539 [PubMed - as supplied by publisher]

Source: The British Journal of Radiology - May 11, 2018 Category: Radiology Authors: Timon G, Ciardo D, Bazani A, Marvaso G, Riva G, Volpe S, Volpe S, Renne G, Petralia G, Zerini D, Rojas DP, Dicuonzo S, Maestri D, Pansini F, Cambria R, Fodor C, Cattani F, Golino F, Scroffi V, De Lorenzo D, De Cobelli O, Orecchia R, Jereczek-Fossa BA Tags: Br J Radiol Source Type: research